

RESPIRATORY VIRUS IMMUNIZATIONS

DISEASE	WHO?	WHAT?	EFFECTIVENESS	WHEN?
FLU	6 months and older	Vaccine that targets 3 strains of seasonal influenza	Reduces risk of going to the doctor by 53%	By the end of October
COVID-19	6 months and older (12 years and older for Novavax)	Seasonal formula: -Comirnaty (Pfizer) -Spikevax (Moderna) -Novavax	2023-24 formula reduced risk of symptomatic infection by 54%	3 months post infection OR at least 8 weeks after previous dose
RSV (OLDER ADULTS)	60 years and older	-Arexvy (GSK) -Abrysvo (Pfizer)	83% effective in preventing lung infections in first season; 56% effective in second season 89% effective in preventing lung infections in first season; durable protection	Late summer and early fall
RSV (MATERNAL)	People 32-36 weeks pregnant (protection passes to baby for first 6 months of life)	-Abrysvo (Pfizer)	Severe illness 82% less likely in first 3 months of life; 69% less likely after 6 months	September through January, during 32 to 36 weeks of pregnancy
OR				
RSV (MONOCLONAL ANTIBODY)	1st RSV season: All infants <8 months 2nd RSV season: High-risk infants 8-19 months, including American Indians	-Beyfortus (Sanofi)	70-90% effective at protecting infants from hospitalization; protection lasts 4-6 months (~1 RSV season)	October through March